The misinformation is rampant, the adverse effect expectations are wildly off, and the patient psychology is complex.
Glucagon-like peptide-1 (GLP-1) receptor agonists have rapidly become some of the most prescribed medications in primary care, endocrinology, and obesity medicine.1 They are effective and transformative for many patients, yet they are some of the most poorly understood medications pharmacists counsel patients on at the pharmacy counter.
After 5 years in community pharmacy and hundreds of GLP-1 counseling conversations, I have learned that the difference between a patient who succeeds long-term and one who quits at week 2 often comes down to what happens in the first conversation at the dispensing counter. The misinformation is rampant, the adverse effect expectations are wildly off, and the patient psychology is complex.
With that in mind, below are 7 counseling pearls I wish every community pharmacist knew: practical insights from the counter that make a real difference in patient adherence and long-term outcomes.
By the time a patient leaves my counter on day 1, they have usually already decided whether they're going to stick with this medication. In my experience, the first-dose experience and the expectations they bring to it predict success or failure more than any clinical factor.
One thing I see repeatedly is that patients arrive at my counter having heard alarming secondhand accounts of severe adverse effects or rare complications. Most of the time, the story has been retold so many times that the original clinical context is gone. When a patient expresses concern about starting a GLP-1 because a loved one had a frightening experience, it is worth gently exploring what happened—often, that family member encountered unexpected nausea or other manageable adverse effects that, without proper preparation, can feel alarming or even dangerous.
This is where pharmacist counseling becomes critical. Patients need explicit reassurance; not false comfort, but honest framing. “Here’s what’s common. Here’s what’s rare. Here’s what you should contact your physician about. Here’s what I can help with.”
The most common reason patients discontinue treatment early is not pancreatitis or any rare adverse event. It is that they spent several days unable to keep water down because nobody warned them to eat smaller, blander meals and avoid fatty foods.
A 5- to 10-minute conversation about realistic week 1 expectations, what to eat, what to avoid, and when to call the prescriber prevents most early discontinuations. This is a pharmacist’s job. We are usually the first and most accessible clinical touchpoint.
Every GLP-1 has a built-in titration schedule for a reason. Skipping or compressing it dramatically increases the rate of severe gastrointestinal adverse effects and patient discontinuation. Most often, I see a patient who does well on the starter dose, decides they want faster weight loss, and pushes their prescriber to titrate faster. Without pharmacists’ input, the prescriber may accommodate. Two weeks later, the patient is vomiting, dehydrated, and convinced the medication is not for them.
As pharmacists, we are positioned to counsel patients on what the dose escalation schedule means. The starting dose is intentionally low, not to minimize efficacy, but to let their body adjust to slowed gastric emptying. Weight loss is meaningful but gradual. Most patients see substantial changes by month 3 to 4, not week 2.
When counseling, be explicit. Educate patients that if they rush the dosing, they will feel worse, not better.
Delayed gastric emptying affects oral medication absorption in clinically significant ways. As pharmacists, we need to flag these at dispensing time.
Key interactions to counsel on include the following2:
These conversations do not happen in the prescriber’s office. They happen at the pharmacy counter. Own that role.
Many patients come back to the pharmacy reporting, “The pen didn't work.” When I troubleshoot, I find one of 3 issues: they removed the needle cap but not the inner needle shield, they did not hold the button long enough, or they injected into a site they were told to avoid.
Spend 2 to 3 minutes demonstrating the pen with a patient. Show them the inner cap, how long to hold the button, and the rotation sites. This single intervention dramatically increases adherence.
Many patients are too embarrassed to ask for help. Your willingness to show them removes that barrier.
The general guidance is that if it has been less than 5 days since the missed dose, take it as soon as possible. If it has been more than 5 days, skip it and resume on the regular day.3 Without clear counseling, however, patients often double up, take 2 doses too close together, or stop entirely because they do not know what to do. Write down the guidance and give patients a card or handout.
Coverage for GLP-1s, particularly for weight management, is inconsistent and frequently changes. Patients regularly arrive at the pharmacy counter expecting one medication only to find their plan covers something else or nothing at all.
From a clinical standpoint, this matters because coverage for weight management is far less common than coverage for diabetes, even though the medications are identical. Additionally, prior authorizations can delay therapy or result in initial prescriptions for less effective alternatives; manufacturer savings cards work for some patients but not federal beneficiaries; and compounded versions exist but with variable quality.4
Pharmacists are the ones navigating these barriers with patients. Their counseling on savings programs, alternative formulations, or when to loop in the prescriber to appeal a denial directly impacts whether patients stay on therapy.
Across hundreds of counseling conversations, I have found that the patients who achieve durable success share 4 traits:
Mohammed Chammout, PharmD, is a community pharmacist with more than 5 years of clinical and patient-facing experience in Dearborn, Michigan. His practice focus includes GLP-1 receptor agonist counseling, diabetes management, and the regulatory and practical aspects of compounded peptide therapeutics. He writes about practical pharmacology for health care professionals and patients.
Patients who view GLP-1s as a medication they only take until they hit their goal often regain most or all weight within a year. That is not a failure of the medication. That is a failure of expectations.
This is the counseling conversation worth having early. “How long do you think you’ll take this?” is a question that opens a useful discussion about chronic disease management.
GLP-1s are remarkable medications, and the patients who do well on them often consider them life-changing. But success or failure often hinges on the counseling that happens at our counter, the first conversation, the technique demonstration, the drug interaction check, and the realistic expectations.
Our prescriber colleagues write the script. We are the ones who make it work in real life.
